--- title: "Veru (VERU) news: reverse split and class action" url: "https://aibio.space/companies/veru/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VERU reverse split and class action news: Veru completes 1-for-10 reverse stock split on Nasdaq. Veru Inc. (NASDAQ: VERU), United States." --- VERU Veru Inc. NASDAQ · United States # Veru (VERU) news VERU reverse split and class action news Legal · 2026-08-10 ## [Veru faces securities class action and five derivative suits over sabizabulin statements](https://aibio.space/news/veru-faces-securities-class-action-five-derivative-suits-sabizabulin/) Veru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses. ## Latest Veru news 1. 2026-08-10 Legal [Veru faces fraud and warranty suit from the buyer of its FC2 business](https://aibio.space/news/veru-faces-fraud-warranty-suit-buyer-fc2-business/) Clear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses. 2. 2025-08-27 Listings [Veru regains compliance with Nasdaq minimum bid price rule](https://aibio.space/news/veru-regains-compliance-nasdaq-minimum-bid-price-rule/) A Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024. 3. 2025-08-12 Listings [Veru completes 1-for-10 reverse stock split on Nasdaq](https://aibio.space/news/veru-completes-1-10-reverse-stock-split-nasdaq/) Veru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count. 4. 2025-01-03 Distress [Veru sells FC2 female condom business to Clear Future for $18.0 million in cash](https://aibio.space/news/veru-sells-fc2-female-condom-business-clear-future-18-0-million-cash/) The sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement. 5. 2025-01-03 Distress [Veru closes $18.0 million sale of FC2 female condom business](https://aibio.space/news/veru-closes-18-0-million-sale-fc2-female-condom-business/) Veru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds. ## Veru at a glance - **Ticker**: VERU - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $23.9 million ### Related companies - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) NASDAQ: ERNA - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO - [Adicet Bio](https://aibio.space/companies/adicet-bio/) NASDAQ: ACET - [Mustang Bio](https://aibio.space/companies/mustang-bio/) NASDAQ: MBIO - [Scorpius Holdings](https://aibio.space/companies/scorpius/) OTC: SCPX - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NASDAQ: NEUP ### Also on NASDAQ - [Cytek Biosciences](https://aibio.space/companies/cytek-biosciences/) CTKB - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD - [Immunovant](https://aibio.space/companies/immunovant/) IMVT - [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) SNTI - [Climb Bio](https://aibio.space/companies/climb-bio/) CLYM - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) KPRX ## What Veru does Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Its two late-stage new chemical entities are enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 RA drugs more tissue selective for fat loss and preservation of lean mass. The company reports a positive Phase 2b QUALITY study of enobosarm in older patients who are overweight or obese and receiving a GLP-1 RA, and plans a Phase 2b PLATEAU trial in patients with obesity receiving tirzepatide (ZEPBOUND). Sabizabulin is an oral microtubule disruptor that the company is exploring for inflammation in atherosclerotic cardiovascular disease, with a possible small Phase 2 proof-of-concept study in patients with stable coronary artery disease. The company plans to prioritize internal cash and future financing proceeds for enobosarm. Veru sold its FDA-approved FC2 Female Condom on December 30, 2024. The filing describes the company's move from a single-product business to a biopharmaceutical company after its 2016 acquisition of Aspen Park Pharmaceuticals. | Product or program | What it is | Stage | |---|---|---| | Enobosarm | Oral SARM for weight reduction and preservation of lean mass alongside GLP-1 RA therapy | positive Phase 2b QUALITY study; Phase 2b PLATEAU planned | | Sabizabulin | Oral microtubule disruptor for inflammation in atherosclerotic cardiovascular disease | exploring clinical development; small Phase 2 proof-of-concept study planned | Summarised from the company's [10-K filed Dec 17, 2025](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/veru20250930_10k.htm). ## Veru annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$15.6 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | [$12.8 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | | Net income (loss) | [-$22.7 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | [-$37.8 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | | Cash from operations | [-$30.0 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | [-$21.7 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | | Cash and equivalents | [$15.8 million](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/) | [$24.9 million](https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $23.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Veru Did Veru do a reverse stock split? Our latest story on this, dated Aug 12, 2025: "Veru completes 1-for-10 reverse stock split on Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/veru-completes-1-10-reverse-stock-split-nasdaq/). Is there a class action against Veru? Our latest story on this, dated Aug 10, 2026: "Veru faces securities class action and five derivative suits over sabizabulin statements". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/veru-faces-securities-class-action-five-derivative-suits-sabizabulin/). What is the ticker symbol of Veru? Veru Inc. trades under the ticker VERU on NASDAQ. Where is Veru listed? Veru Inc. is listed on NASDAQ. What is the SEC CIK of Veru? The SEC Central Index Key (CIK) for Veru Inc. is 863894. Its filings are on SEC EDGAR. How many shares does Veru have outstanding? 17,050,320 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Veru listed under? Our directory records Veru Inc. under United States. What does Veru do? Our directory classifies Veru Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Veru? The ISIN recorded for Veru Inc. is US92536C2026. Does aibio.space cover Veru? aibio.space lists Veru Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Veru incorporated? SEC records list its state or country of incorporation as WI. What does Veru develop? Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Its two late-stage new chemical entities are enobosarm and sabizabulin. What is Enobosarm from Veru? Enobosarm: Oral SARM for weight reduction and preservation of lean mass alongside GLP-1 RA therapy Stage: positive Phase 2b QUALITY study; Phase 2b PLATEAU planned. What is Sabizabulin from Veru? Sabizabulin: Oral microtubule disruptor for inflammation in atherosclerotic cardiovascular disease Stage: exploring clinical development; small Phase 2 proof-of-concept study planned. Is Veru profitable? Veru Inc. reported a net loss of $22.7 million for the fiscal year ended Sep 30, 2025, and used $30.0 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Veru Members talk about Veru (VERU). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Veru, newest first. Each line links the filing it comes from. 1. 2026-07-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/863894/000119312526294490/d60672d424b5.htm) 2. 2025-09-26 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774925029912/0001437749-25-029912-index-headers.html) 3. 2025-08-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774925027858/veru20250827_8k.htm) 4. 2025-08-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774925026037/veru20250806_8k.htm) 5. 2025-07-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774925023521/veru20250724c_8k.htm) 6. 2025-06-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/863894/000114036125022074/ny20048127x2_def14a.htm) 7. 2025-05-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/863894/000114036125018161/ny20048127x1_pre14a.htm) 8. 2025-02-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/863894/000119312525042467/d821788d8k.htm) 9. 2025-01-03 Distress Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,1.02,2.01,2.04,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/veru20241220_8k.htm) 10. 2024-12-16 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/veru20240930_10k.htm) 11. 2024-12-16 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/veru20240930_10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VERU on TradingView](https://www.tradingview.com/symbols/NASDAQ-VERU/). ## SEC filings and registration - **SEC name**: Veru Inc. - **CIK**: 863894 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: VERU (Nasdaq) - **State or country of incorporation**: WI - **Fiscal year ends**: September 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2916 N. MIAMI AVENUE, MIAMI, FL, 33127 - **Phone**: 3125959123 - **Shares outstanding**: 17,050,320 as of 2026-08-06 (10-Q filed 2026-08-10) - **Former names**: FEMALE HEALTH CO ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118d8k.htm) filed 2026-09-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580d8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/863894/000119312526294507/d124945d8k.htm) filed 2026-07-02 - [424B5](https://www.sec.gov/Archives/edgar/data/863894/000119312526294490/d60672d424b5.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/veru20260331_10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190d8k.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000863894), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Veru Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VERU, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Veru Inc. - **Ticker**: VERU - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US92536C2026 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VERU/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/veru/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Veru (VERU) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/veru/